Home / Health / Health Canada Approves New Cancer Drug Biosimilar
Health Canada Approves New Cancer Drug Biosimilar
1 May
Summary
- CuraTeQ Biologics' biosimilar Bevqolva received Health Canada approval.
- Bevqolva is a biosimilar version of Roche's cancer drug Avastin.
- The drug targets tumor vascular growth to treat various cancers.
Health Canada's Biologics and Radiopharmaceutical Drugs Directorate has granted a Notice of Compliance to CuraTeQ Biologics for Bevqolva, its bevacizumab biosimilar. This development marks a significant step for Aurobindo Pharma's subsidiary in the Canadian market.
Bevacizumab is a monoclonal antibody that functions by inhibiting tumor vascular growth. It is a crucial component in the treatment regimen for several types of cancer, including colorectal and lung cancers. Bevqolva offers a biosimilar alternative to Avastin, the reference product developed by Roche/Genentech, potentially increasing treatment options and accessibility for Canadian patients.
Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.
